The acquisition adds analytical characterization and molecular design software capabilities to Revvity Signals’ platform.
Revvity Inc has entered into a definitive agreement to acquire ACD/Labs, a provider of scientific software solutions for analytical characterization and molecular design in pharmaceutical and material sciences markets. The transaction is expected to close in late Q4 2025.
The acquisition will integrate ACD/Labs’ analytical and process chemistry expertise into Revvity Signals’ research informatics platform. ACD/Labs’ tools help scientists identify and characterize molecules, monitor purity and quality, and support production processes across pharmaceutical and chemical R&D workflows.
ACD/Labs brings several software platforms to the deal, including the Spectrus Platform for spectral analysis and the Percepta Platform for AI-driven molecular property and ADMET prediction. Additional applications include Katalyst D2D for parallel and high-throughput experimentation, Luminata for pharmaceutical chemistry and manufacturing decision support, and ADMS for enterprise analytical data management.
“By integrating ACD/Labs’ technologies into the Revvity Signals platform, we’re giving our customers across pharmaceuticals and material sciences a truly unified SaaS environment—one that connects molecular design, analytical science, and manufacturing quality control within a single, end-to-end solution,” says Kevin Willoe, president of Revvity Signals Software, in a release.
The combined platforms aim to support scientific workflows from discovery and development through scale-up and manufacturing. Revvity says the integration will help scientists interpret, manage, and act on complex data with greater speed and confidence.
“For more than three decades, our scientists, informaticians, and software developers have been recognized as leaders in analytical and chemical intelligence,” says Daria Thorp, president and CEO of ACD/Labs, in a release. “Joining the Revvity Signals team brings together two industry leaders with a shared commitment to innovation in scientific software.”
Financial terms of the transaction were not disclosed.
